2026 — Jaffal & Jaffal — PRISMA systematic review of gene therapy in chronic pain (FM + CRPS + neuropathy + arthritis)
One-paragraph summary
PRISMA-screened systematic review of gene-therapy strategies in chronic pain, drawing on Web of Science, Medline, Scopus, and Google Scholar (January 2010 – March 2023). 512 records identified; 18 studies met inclusion criteria across four conditions: neuropathic pain, arthritis, fibromyalgia, and complex regional pain syndrome (CRPS). Strategies reviewed: RNA interference (RNAi), viral vector delivery, CRISPR/Cas9, gene replacement therapy, and endogenous opioid gene delivery. Findings: RNAi and gene replacement therapy emerge as preclinical-validated tools for pain reduction and quality-of-life improvement by modulating pain-associated genes; CRISPR/Cas9 with site-directed nanoparticle delivery offers candidate long-term relief but persistent safety concerns; endogenous opioid gene delivery represents a novel substrate-targeting class. For the project, this paper closes the missing systematic-review-level anchor for §12.10 advanced-therapy / gene-therapy-tier added in v0.3.4 as the project's only currently-named cure arm under the strict cure-vs-treatment classification. §12.10 had been asserted in the white paper without a PRISMA-systematic-review documentation depth; Jaffal & Jaffal supplies the formal review-of-evidence with FM-specific preclinical coverage included. The 18-study evidence base also serves as the prior-art landscape for any future investigator-initiated gene-therapy preclinical → Phase 1 pathway in FM.
Claims as triples
gene_therapy_chronic_pain — preclinical_evidence_in → fm_central_only[evidence: PRISMA-screened systematic review including FM preclinical studies; confidence: emerging]gene_therapy_chronic_pain — preclinical_evidence_in → crps[evidence: same; confidence: emerging]RNAi — modulates → pain_associated_genes[evidence: 18-study evidence base reviewed; confidence: emerging (preclinical)]viral_vector_delivery — class_of → gene_therapy_chronic_pain[evidence: review categorization; confidence: established]CRISPR_Cas9 — class_of → gene_therapy_chronic_pain[evidence: same; confidence: established]gene_replacement_therapy — class_of → gene_therapy_chronic_pain[evidence: same; confidence: established]endogenous_opioid_gene_delivery — class_of → gene_therapy_chronic_pain[evidence: same; confidence: emerging]gene_therapy — has_classification → cure_candidate[evidence: §12.10 cure-vs-treatment classification per cure-path-arm-decisions.md; confidence: established (by project framing)]
Triangulation notes
- Closes the §12.10 advanced-therapy-tier systematic-review-anchor gap. Section §12.10 was added in v0.3.4 of the white paper as the project's only currently-named cure arm under the strict cure-vs-treatment classification (cure = elimination of source, not recurring symptom management). The arm was anchored by the cure-path-arm-decisions.md framework and the cross-condition HERV-targeted watchlist (WL-1 through WL-6) but lacked PRISMA-systematic-review-level documentation of preclinical gene-therapy evidence specifically in chronic-pain conditions. Jaffal & Jaffal 2026 provides exactly this: 18 PRISMA-screened studies across FM, CRPS, neuropathy, and arthritis. The §12.10 arm now has formal systematic-review citation depth.
- Provides the prior-art landscape for an FM-stratified Phase 1 gene-therapy pathway. The 18 studies identify which approaches have preclinical validation in FM and which remain unstudied — useful for any future investigator-initiated proposal selecting a specific strategy class to advance to FM-stratified Phase 1.
- Strategic implication for cure-vs-treatment classification. §12.10 is currently the only §12 arm classified as CURE-CANDIDATE under the strict elimination-of-source definition. Most §12.1-§12.9 arms are chronic-management interventions. The systematic-review-level evidence base Jaffal & Jaffal provides is what makes §12.10 defensible as a cure-research investment rather than speculative wishful thinking — the preclinical evidence in chronic-pain populations is real.
- Cross-condition gene-therapy class observation. That gene therapy has been studied across neuropathic pain, arthritis, FM, and CRPS — four conditions with substantially different pathophysiology — suggests the class is mature enough to support condition-stratified trial design. This is the kind of cross-condition framework the project's three-axis cube + cross-condition HERV watchlist anticipates.
Open questions raised
- Of the 18 PRISMA-included studies, which specifically address FM versus which address CRPS / neuropathy / arthritis? (Need full-text read for FM-specific subset identification.)
- Which RNAi or gene-replacement targets have the strongest preclinical signal in FM models, and how do those targets map onto the Goebel passive-transfer paradigm and the Seefried 2025 9-binding-cluster autoantigen space?
- What's the right design for an FM-stratified Phase 1 gene-therapy trial — direct-to-tissue (e.g., intrathecal AAV) vs systemic vs ex-vivo cell-modification approaches?
- Does any of the 18 PRISMA-included studies use a HERV-targeted gene-therapy strategy (e.g., CRISPR knockdown of HERV-W ENV transcription)? Would be the most direct test of H1's cure-tractability.
- What would the cost / IND / regulatory pathway look like for an investigator-initiated stratified pilot of one of the FM-validated approaches?